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Aim and method: There have been few reports about the risk of ischemic stroke in elderly
patients with non-valvular paroxysmal atrial ﬁbrillation (NVPAF). The aim of this study was
to evaluate the validity of the guidelines issued by the Japanese Circulation Society to prevent
ischemic stroke for NVPAF in patients without a high risk of ischemic stroke. The risk
evaluation was made based on the CHADS2 Score. However, we excluded age in this study,
but included coronary disease. This study investigated a total of 150 patients with paroxysmal
atrial ﬁbrillation (AF) who did not have a high risk of stroke (117 men and 33 women, mean
age 68 12 years). The patients were divided into three groups according to age: the patients
who were less than 60 years old (Group I, N ¼ 58, Antithrombic therapy (+) = 18), those
who were between 60 and 75 years old (Group II, N ¼ 68, Antithrombic therapy (+) = 36)
and those who were more than 75 years old (Group III, N ¼ 24, Antithrombic therapy
(+) = 7). The annual rates of thromboembolism among three groups were retrospectively
analyzed. The mean follow-up periods were 56 37 months.
Results: (1) The annual rate of thromboembolism in Group III (4.0%) was signiﬁcantly
higher than in Group I (1.4%) and Group II (1.8%) (P < 0:05). (2) The annual rates of
thromboembolism in patients without antithrombotic therapy were 2.1% in Group I, 1.3% in
Group II and 3.9% in Group III. The annual rate was signiﬁcantly lower in Group II than in
Group III (P < 0:05). (3) The annual rates of thromboembolism with aspirin treatment (80–
100mg/day) were 0% in Group I, 3.0% in Group II and 8.4% in Group III. There was a
signiﬁcant diﬀerence in the annual rate among the three groups (P < 0:05). (4) The annual
rate of thromboembolism in patients with warfarin treatment was 0% in Group I, 1.5% in
Group II and 0% in Group III (P ¼ NS among 3 groups).
Conclusion: Antithrombic therapy is required in elderly patients with NVPAF to prevent
ischemic stroke. Antithrombic therapy with Warfarin, but not aspirin, reduces ischemic stroke
in patients with NVPAF regardless of their age.
(J Arrhythmia 2009; 25: 81–88)
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Introduction
The incidence of AF is increasing in Japan as the
population ages. AF not only decreases the quality of
life, but also may sometimes be associated with
thromboembolism or heart failure,1,2) and it worsens
the cardiovascular prognosis of patients with left
ventricular dysfunction.3) The Japanese Circulation
Society (JCS) Guidelines4) that recommends phar-
macologic therapy to prevent embolism in patients
with nonvalvular AF should be selected on the basis
of risk assessment.
However, in clinical practice, thromboembolism
occasionally develops in non-elderly patients with
nonvalvular AF. Japanese AF patients younger than
60 years of age have been reported to suﬀer a death
rate from ischemic stroke 2 to 3 times higher in
comparison to patients who do not have AF and the
cardiovascular prognosis also tends to be more
serious in AF patients.5) Therefore, the prevention
of thromboembolism in non-elderly AF patients who
are generally believed to be at low risk is important,
but it remains uncertain whether the antithrombotic
therapy recommended by the JCS Guidelines pro-
vides a valid strategy.
In the present study, we retrospectively examined
the cardiovascular prognosis of antithrombotic ther-
apy according to the JCS Guidelines in low-risk
patients with NVPAF.
Methods
Patients and deﬁnitions
Among 342 patients with paroxysmal AF in whom
12-lead and Holter electrocardiogram (ECG) con-
ﬁrmed the presence of AF consistent with their
symptoms, 150 patients (117 men and 33 women
with a mean age of 68 12 years) who had no risk
factors for thromboembolism that did not show the
valvular heart disease by transthoracic echocardiog-
raphy were enrolled. All patients attended our
hospital at intervals of 2–4 weeks and presented
for the treatment of symptoms that interfered with
their daily activities. The study was conducted from
June 1993 to August 2005, with a mean follow-up
period of 56 37 months (range: 12–127 months).
All patients underwent history hearing, chest
radiography, exercise testing and echocardiography.
In addition, pulmonary function tests, chest com-
puted tomography and cardiac catheterization were
performed when it was considered to be necessary by
the physician. Cerebral thromboembolism was diag-
nosed on the basis of symptoms and the detection of
an infarct  3mm in size by computed tomography
or magnetic resonance imaging of the brain. Hyper-
tension was deﬁned as a systolic blood pressure of
 140mmHg or a diastolic blood pressure of  90
mmHg on casual clinic monitoring.6) Paroxysmal
AF was deﬁned as the spontaneous onset and
termination of one or more episodes of tachycardia
within 2–7 days,7) while progression to chronic AF
was deﬁned as the absence of conﬁrmation of sinus
rhythm during a 6-month period despite treatment
with aggressive antiarrhythmic drug therapy. In this
study, we determined the CHADS2 score8) and
evaluated the risk. However, we excluded age in this
study, but included coronary disease. Therefore,
the risk factors for thromboembolism were a
previous transient ischemic attack or cerebral in-
farction, hypertension, diabetes mellitus, coronary
artery disease and recent heart failure.4) In addition,
major bleeding was deﬁned as either a hemorrhage
which required a transfusion or an intracranial
hemorrhage.
Patients were excluded from the study if they had
heart failure, serious bradyarrhythmias (sick sinus
syndrome, atrioventricular block, or intraventricular
conduction disturbance), or hepatic or renal dys-
function. Women who might be pregnant and
patients were receiving -blockers or T-type calcium
channel blockers were also excluded.
Protocol for antiarrhythmic drug therapy
All patients received antiarrhythmic drug therapy
for maintenance of sinus rhythm (rhythm control
therapy). Patients with a left ventricular ejection
fraction of  40% on transthoracic echocardiogra-
phy were assigned by the sealed envelop method
to receive disopyramide (300mg/day), aprindine
(60mg/day), or cibenzoline (300mg/day) as the
ﬁrst-line agent after spontaneous or pharmacologic/
electrical deﬁbrillation. Patients who had recurrence
of AF were assigned by the sealed envelope method
to receive pilsicainide (150mg/day), ﬂecainide
(150mg/day), or bepridil (150mg/day) as the
second-line agent. Those who had repeated recur-
rence of AF were treated with amiodarone (200mg/
day) or a diﬀerent class I antiarrhythmic drug as the
third-line agent. On the other hand, patients with a
left ventricular ejection fraction of < 40% on trans-
thoracic echocardiography were assigned by the
sealed envelope method to receive aprindine (60mg/
day) or bepridil (150mg/day) as the ﬁrst or second-
line agent after spontaneous or pharmacologic/
electrical deﬁbrillation. Patients who were unrespon-
sive to these two drugs and had recurrent AF were
given amiodarone (200mg/day) as the third-line
agent.
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The details of the preventive eﬀect on recur-
rence of AF achieved with these protocols have
already been reported.9) In all patients, we assessed
symptoms and recorded a standard 12-lead ECG
after they started the assigned antiarrhythmic drugs
or 2–4 weeks after changing therapy and per-
formed simpliﬁed ambulatory ECG monitoring at
each hospital visit to assess the presence or
absence of sinus rhythm. If the attending physician
considered it necessary, a Holter ECG recording
was obtained every three months to identify the
presence or absence of AF. At the time of
changing antiarrhythmic drugs, each patient whose
ECG conﬁrmed the maintenance of sinus rhythm
underwent measurement of the plasma atrial
natriuretic peptide level using blood obtained from
an upper limb vein while the subject was at rest in
the supine position. On the other hand, patients in
whom AF became chronic despite antiarrhythmic
therapy were treated orally with -blockers, cal-
cium antagonists, or digitalis for ventricular rate
control.
Protocol for antithrombotic therapy
Antithrombotic therapy was provided at the dis-
cretion of the attending physician before the JCS
Guidelines were released in November 2001. There-
after, antithrombotic therapy was mainly selected in
accordance with the JCS Guidelines. The dose of
aspirin was set at 81–100mg/day and the dose of
warfarin was set to maintain an international
normalized ratio (INR) of 1.6–2.6. The INR range
during follow-up was 1.3–3.1 (mean: 1.9).
In accordance with the recommendations of the
JCS Guidelines, the patients were classiﬁed into
three age groups: < 60 years of age (group I, N ¼
58); 60–75 years of age (group II, N ¼ 68); and
> 75 years of age (group III, N ¼ 24). The clinical
characteristics of the patients in each group were
compared after stratiﬁcation according to the pres-
ence or absence of antithrombotic therapy. There-
after, the annual rate of thromboembolic events
stratiﬁed according to the presence or absence of
antithrombotic therapy and the incidence of compli-
cations due to antithrombotic therapy were com-
pared among the three groups.
Statistical analysis
Results are expressed as the mean  standard
deviation. The One-way ANOVA test was used for
comparisons of the continuous variables among each
group, receiving antithrombotic therapy and not
receiving antithrombotic one. The chi square test
was used for comparisons of the proportions among
the age groups. Diﬀerences were considered to be
signiﬁcant at the level of P < 0:05 for all analyses.
Results
Clinical proﬁle
1. Patients under age 60 (group I; Table 1)
The left atrial diameter measured by transthoracic
echocardiography was signiﬁcantly greater in the
patients receiving antithrombotic therapy (group A,
N ¼ 18) than in those not receiving antithrombotic
therapy (group B, N ¼ 40; P < 0:05). No other
signiﬁcant diﬀerence were recognized between
groups A and B. The underlying heart disease
included sick sinus syndrome in two patients, hyper-
trophic cardiomyopathy in one, myocarditis in one
and an atrial-septal defect in one.
2. Patients between ages 60 and 75 (group II;
Table 2)
The left atrial diameter on transthoracic echocar-
diography, the prevalence of underlying heart dis-
ease and the percentage of patients on oral renin-
angiotensin-aldosterone system (RAAS) inhibitors
were all signiﬁcantly greater for the patients receiv-
ing antithrombotic therapy (group A, N ¼ 36) than
for those without antithrombotic therapy (group B,
N ¼ 32; P < 0:05), but no other signiﬁcant dif-
ferences were recognized. The underlying heart
diseases included dilated cardiomyopathy in six
patients, sick sinus syndrome in four patients,
hypertrophic cardiomyopathy in three, atrial septal
defect in two, myocarditis in one and syndrome X in
one.
3. Patients more than age 75 (group III; Table 3)
The left atrial diameter on transthoracic echocar-
diography, the duration of disease and the percentage
of patients on oral RAAS inhibitors were signiﬁ-
cantly greater for patients receiving antithrombotic
therapy (group A, N ¼ 7) than for those without
antithrombotic therapy (group B, N ¼ 17; P < 0:05),
but no other signiﬁcant diﬀerences were recognized.
The underlying heart disease was hypertrophic
cardiomyopathy in three patients, dilated cardiomy-
opathy in two, sick sinus syndrome in one, and
syndrome X in one.
4. All patients (Table 4)
The proportions of male patients and patients with
organic heart disease were signiﬁcantly greater for
group I than for groups II and III (P < 0:05). The
percentages patients who habitually smoked or took
alcohol were signiﬁcantly greater for group I than for
group III (P < 0:01, P < 0:05). On the other hand,
the left atrial diameter (LAD) was signiﬁcantly
greater in group III than in group I (P < 0:05). The
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percentage of hyperlipidemia was signiﬁcantly great-
er for group III than for groups I and II (P < 0:01).
Otherwise, there were no signiﬁcant diﬀerences
among the three groups.
Incidence and annual rate of thromboembolism
in patients with paroxysmal AF (Table 5)
The overall annual rate of thromboembolism was
signiﬁcantly higher in group III than in groups I and
Table 1 Clinical characteristics of patients less than 60 years of age (Group I)
Antithrombotic
Therapy (+)
Antithrombotic
Therapy () P-value
Number 18 40
Age (y.o) 50.4  6.5 48.6  11.3 N.S.
Men : Female 18:0 34:6 N.S.
Smoking 8 (44%) 22 (55%) N.S.
Hypertension 0 (0%) 0 (0%) N.S.
Diabetes Mellitus 0 (0%) 0 (0%) N.S.
Hyperlipidemia 2 (11%) 3 (8%) N.S.
Hyperuricemia 3 (17%) 2 (5%) N.S.
Alcohol habits 13 (72%) 26 (65%) N.S.
Organic heart disease 1 (6%) 4 (10%) N.S.
Organic pulmonary disease 1 (6%) 1 (3%) N.S.
Suffering periods (months) 24.5  37.8 20.1  28.8 N.S.
LVDd (mm) 44.6  6.0 46.1  5.2 N.S.
LAD (mm) 33.6  4.4 30.8  4.2 P < 0.05.
LVEF (%) 71.8  9.2 69.6  9.5 N.S.
ANP during SR (pg/ml) 26.1  18.8 34.0  54.9 N.S.
RAAS-I 0 (0%) 2 (5%) N.S.
Continuous values are the mean SD. Values in parentheses are %.
LVDd: left ventricular end-diastolic dimension, LAD: left atrial dimension, LVEF: left ventricular ejection fraction,
ANP: atrial natriuretic peptide, SR: sinus rhythm, RAAS-I: renin-angiotensin-aldosterone system inhibitors
Table 2 Clinical characteristics of patients between 60 and 75 years of age (Group II)
Antithrombotic
Therapy (+)
Antithrombotic
Therapy () P-value
Number 36 32
Age (y.o) 69.2  4.3 48.6  11.3 N.S.
Men : Female 24:12 26:6 N.S.
Smoking 8 (22%) 22 (55%) N.S.
Hypertension 0 (0%) 0 (0%) N.S.
Diabetes Mellitus 0 (0%) 0 (0%) N.S.
Hyperlipidemia 5 (14%) 3 (8%) N.S.
Hyperuricemia 1 (3%) 2 (5%) N.S.
Alcohol habits 19 (53%) 26 (65%) N.S.
Organic heart disease 13 (36%) 4 (10%) P < 0.05
Organic pulmonary disease 3 (9%) 1 (3%) N.S.
Suffering periods (months) 11.9  24.4 20.1  28.8 N.S.
LVDd (mm) 46.0  6.8 46.1  5.2 N.S.
LAD (mm) 35.1  6.4 30.8  4.2 P < 0.05
LVEF (%) 67.7  14.8 69.6  9.5 N.S.
ANP during SR (pg/ml) 48.6  61.6 34.0  54.9 N.S.
RAAS-I 7 (19%) 2 (5%) P < 0.05
Continuous values are the mean SD. Values in parentheses are %.
LVDd: left ventricular end-diastolic dimension, LAD: left atrial dimension, LVEF: left ventricular ejection fraction,
ANP: atrial natriuretic peptide, SR: sinus rhythm, RAAS-I: renin-angiotensin-aldosterone system inhibitors
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II (P < 0:05). The annual rate of thromboembolism
in the patients receiving antithrombotic therapy
tended to be higher in group III than in group I
(P ¼ 0:064).
Table 3 Clinical characteristics of patients more than 75 years of age (Group III)
Antithrombotic
Therapy (+)
Antithrombotic
Therapy () P-value
Number 7 17
Age (y.o) 77.6  1.5 80.2  3.6 N.S.
Men : Female 5:2 10:7 N.S.
Smoking 1 (14%) 3 (18%) N.S.
Hypertension 0 (0%) 0 (0%) N.S.
Diabetes Mellitus 0 (0%) 0 (0%) N.S.
Hyperlipidemia 4 (57%) 4 (24%) N.S.
Hyperuricemia 0 (0%) 0 (0%) N.S.
Alcohol habits 3 (43%) 6 (35%) N.S.
Organic heart disease 2 (29%) 5 (29%) N.S.
Organic pulmonary disease 0 (0%) 2 (12%) N.S.
Suffering periods (months) 67.0  70.1 18.4  26.1 P < 0.05
LVDd (mm) 45.0  5.1 43.9  5.3 N.S.
LAD (mm) 37.2  6.5 33.7  5.3 P < 0.05
LVEF (%) 65.6  12.4 69.4  9.7 N.S.
ANP during SR (pg/ml) 76.2  25.3 52.8  26.5 N.S.
RAAS-I 2 (29%) 0 (0%) P < 0.05
Continuous values are the mean SD. Values in parentheses are %.
LVDd: left ventricular end-diastolic dimension, LAD: left atrial dimension, LVEF: left ventricular ejection fraction,
ANP: atrial natriuretic peptide, SR: sinus rhythm, RAAS-I: renin-angiotensin-aldosterone system inhibitors
Table 4 All patients
Group I Group II Group III P-value
Number 58 68 24
Age (y.o) 47.2  10.0 68.6  4.5 79.4  3.3
Male:female 52:6 5:18 15:9 P < 0.05 Group I vs II,III
Smoking 30 (52%) 30 (44%) 4 (17%) P < 0.01 Group I vs III
Hypertension 0 (0%) 0 (0%) 0 (0%) N.S.
Diabetes mellitus 0 (0%) 0 (0%) 0 (0%) N.S.
Hyperlipidemia 5 (9%) 8 (12%) 8 (33%) P < 0.01 Group I,II vs III
Hyperuricemia 5 (9%) 3 (4%) 0 (0%) N.S.
Alcohol habits 39 (67%) 45 (59%) 9 (38%) P < 0.05 Group I vs III
Organic heart disease 5 (9%) 17 (25%) 7 (29%) P < 0.05 Group I vs II,III
Organic pulmonary disease 2 (3%) 4 (6%) 2 (8%) N.S.
Suffering periods (months) 21.5  31.6 16.7  29.0 32.6  47.6 N.S.
LVDd (mm) 45.7  5.4 45.2  5.9 44.3  5.2 N.S.
LAD (mm) 31.6  4.4 33.1  6.6 34.7  5.7 P < 0.05 Group I vs III
LVEF (%) 70.3  9.4 69.7  12.0 68.3  10.4 N.S.
ANP during SR (pg/ml) 31.2  45.3 41.2  48.9 59.2  27.8 N.S.
RAAS-I 2 (3%) 9 (13%) 2 (8%) N.S.
Patient without AF recurence 31 (53%) 33 (49%) 11 (46%) N.S.
Patient with
conversion to chronic AF 13 (22%) 14 (21%) 7 (29%) N.S.
Continuous values are the mean SD. Values in parentheses are %.
LVDd: left ventricular end-diastolic dimension, LAD: left atrial dimension, LVEF: left ventricular ejection fraction,
ANP: atrial natriuretic peptide, SR: sinus rhythm; RAAS-I, renin-angiotensin-aldosterone system inhibitors
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The annual rate of thromboembolism in patients
receiving aspirin therapy was signiﬁcantly higher in
group III than in groups I and II (P < 0:05).
However, for patients treated with warfarin, there
were no signiﬁcant diﬀerences in the rate among the
three groups. The INR before thromboembolism
occurred in one patient on warfarin therapy was 1.4.
Incidence and annual rate of major bleeding in
patients with paroxysmal AF on antithrombotic
therapy (Table 6)
The annual rate of major bleeding complications
for all patients was 0.9%, and there were no
signiﬁcant diﬀerences among the age groups or
between the aspirin and warfarin groups.
Discussion
Incidence and annual rate of thromboembolism
Large-scale controlled trials performed in Europe
and North America have shown that the annual rate
of thromboembolism in patients with nonvalvular
AF is 3.0–6.3%.10–15) This annual rate is reduced to
3.4–4.7% by treatment with aspirin and to 0.4–2.5%
by warfarin therapy. The reported variation in the
annual rate of thromboembolism may be due to
diﬀerences in the level of risk among the subjects of
the study, as well as diﬀerences in the length of
follow-up. In Japan, the annual rate of thromboemb-
olism in patients with nonvalvular AF has been
reported to be 2.2–4.5%.16–18) Similarly, the annual
rate is reduced to 1.4–4.4% by aspirin therapy, and to
0.7–1.5% by treatment with warfarin. On the other
hand, a meta-analysis of large-scale controlled trials
from Europe and North America has shown that risk
factor-free patients, younger than 65 years old, have
a low annual thromboembolism rate of 1.0%.1)
In contrast, an analysis of 20,000 patients attending
cardiovascular departments in Japan showed that the
annual rate for those under age 60 with nonvalvular
AF was a relatively high 1.8%,19) which was similar
to the current results. Furthermore, a recent Japanese
epidemiologic study indicated that AF increases the
relative risk of death due to ischemic stroke 14.7-
fold and increases the risk of the cardiovascular
death 9.6-fold in patients under 65 years old.20) In the
present study of patients who had nonvalvular AF
without thromboembolic risk factors, three patients
Table 5 Incidence and annual rate of thromboembolism in patients with paroxysmal atrial
ﬁbrillation
Group I Group II Group III All cases
All patients 3/58 6/68 6/24 15/150
annual rate (%) 1.4 1.8yy 4.0&yy 2.4
Without antithrombotic therapy 3/40 3/32 3/11 9/83
annual rate (%) 2.1 2.0 3.9 2.6
With antithrombotic therapy 0/18 3/36 3/13 6/67
annual rate (%) 0 1.7 4.1 1.9
Aspirin 0/9 2/19 3/5 5/33
annual rate (%) 0 2.2yy 8.4&yy 4.2
Warfarin 0/9 1/17 0/8 1/34
annual rate (%) 0 1.5 0 0.5
; p < 0:05, Group I vs Group III
yy; p < 0:05, Group II vs Group III
Table 6 Incidence and annual rate of major bleeding in patients with paroxysmal AF on
antithrombotic therapy
Group I Group II Group III All cases
All patients 58 68 24 150
With antithrombotic therapy 0/18 1/36 2/13 3/67
annual rate (%) 0 0.6 2.5 0.9
Aspirin 0/9 1/19 1/5 2/33
annual rate (%) 0 1.1 3.2 1.3
Warfarin 0/9 0/17 1/8 1/34
annual rate (%) 0 0 2.0 0.6
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under 60 years old were observed to have a
thromboembolism and none of them were on
antithrombotic therapy (7.5%). In this study, the
annual rate of thromboembolism for nonvalvular AF
patients without thromboembolic risk factors was
2.4%.
Adverse effects of antithrombotic therapy
A large-scale controlled Japanese trial evaluating
the preventive eﬀect of aspirin on symptomatic
ischemic stroke in patients with nonvalvular AF
(Japan Atrial ﬁbrillation and Stroke Trial [JAST
study], mean follow-up 2.1 years)21) revealed that the
rate of serious bleeding was about 4 times higher
than in large-scale European and North American
trials. In the present study, the patients were
followed for an average of 4.7 years and the annual
rate of serious bleeding complications associated
with aspirin therapy was 1.3%, which was slightly
higher than that due to warfarin. On the other hand, a
randomized controlled Japanese study of warfarin
therapy for secondary prevention of ischemic stroke
in AF patients showed that anticoagulation with an
INR between 1.5 and 2.1 was able to prevent
recurrence without intracranial hemorrhage, on the
other hand, patients with an INR between 2.2 and 2.7
had an increased frequency of intracranial hemor-
rhage.22) In the present study, low-dose warfarin
therapy was performed with a target INR of 1.6–2.6
and the annual rate of serious bleeding complications
was relatively low at 0.6%. These results suggest
that Japanese patients did not required the same level
of the anticoagulant therapy as those of Western
countries considering that Japanese patients are
prone to bleeding complications. Therefore, a target
INR between 1.6 and 2.6 was considered reasonable
for keeping the rate of serious bleeding complica-
tions low during warfarin therapy. Therefore atten-
tion should be paid to prevent bleeding complica-
tions during aspirin-based and warfarin-based
antithrombotic therapy, especially in older patients.
Limitations
Some limitations of the present study should be
mentioned. First, since all the subjects were on
antiarrhythmic therapy for maintenance of sinus
rhythm, it was impossible to evaluate the eﬀect of
antithrombotic therapy in patients treated with rate
control therapy. The incidence of thromboembolism
among patients with paroxysmal AF is dependent on
their response to antiarrhythmic drug therapy.8) In a
large-scale controlled North American trial (The
Atrial Fibrillation Follow-up Investigation of
Rhythm Management [AFFIRM] study), sinus
rhythm was maintained by rate control therapy in a
relatively high 35% of the subjects.23) In other
words, the outcome for patients in whom sinus
rhythm was maintained may not have been strongly
inﬂuenced by the eﬀect of antithrombotic therapy. In
this study, we did not include duration and frequency
of the paroxysmal AF. It is therefore considered that
further study will be necessary in the future. Second,
the present study was retrospective and observational
in design with some bias in patient characteristics.
Among patients older than age 60, the use of oral
RAAS inhibitors was signiﬁcantly more common for
those receiving antithrombotic therapy than for those
without it. A large-scale controlled North American
trial recently indicated that RAAS inhibitor therapy
reduces the occurrence of ischemic stroke.24) There-
fore, in the present study there is a possibility that
the combination therapy of the RAAS inhibitor may
inﬂuence the annual rate of ischemic stroke. Third,
this study overlaps the period both before and after
the guidelines were established. Therefore, the
choice of the antithrombotic therapy before the
guidelines may have been aﬀected by a drug
selection bias of the attending physician. Finally,
the patient population investigated in this study was
relatively small. Therefore, the one case has a large
inﬂuence on the overall results. As a result, it is
diﬃcult to make any deﬁnitive conclusions based
on the ﬁndings of this study. The validity of the
JCS Guidelines should therefore be assessed by
a multicenter prospective study in the future. In
addition, because of the small number of such cases,
we did not compare the groups which took antith-
rombic therapy with the groups which did not.
Therefore it is thought that further examinations are
necessary.
Conclusions
The JCS recommendations concerning antithrom-
botic therapy for nonvalvular AF appeared to be
valid. To prevent thromboembolism in low-risk
patients on antiarrhythmic (rhythm control) therapy,
it may be advisable to use warfarin rather than
aspirin. However, this study was only conducted
at our institution, and there was a small number of
cases. Therefore, futher investigations with a larger
number of patients and many institutions will be
necessary in the future. In addition, because there are
many patients younger than age 60 associated with
ischemic stroke, further studies might also be
required to clarify the validity of the Japanese
guidelines in the management of younger patients
(under age 60) with NVPAF.
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